Harrow Health, Inc. Stock News

NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the acquisition of Melt Pharmaceuticals, Inc. (Melt), a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and i...

Harrow, Inc. ( HROW ) Q3 2025 Earnings Call November 11, 2025 8:00 AM EST Company Participants Michael Biega - Vice President of Investor Relations & Communications Mark Baum - CEO & Chairman of the Board Andrew Boll - President, CFO & Corporate Secretary Patrick Sullivan - Head of Commercial Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Chase Kni...

Third-Quarter 2025 and Recent Selected Highlights:  Total revenues of $71.6 million, a 45% increase over $49.3 million recorded in the prior-year period GAAP net income of $1.0 million Adjusted EBITDA of $22.7 million Cash and cash equivalents of $74.3 million as of September 30, 2025 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn.

Harrow, Inc. is an ophthalmology company with strong revenue growth, ambitious targets, and a diverse product portfolio including Vevye and Iheezo. HROW targets $280M in 2025 revenue and >$250M per quarter by Q4 2027, leveraging recent acquisitions and biosimilar partnerships. Despite low profitability and modest cash reserves, HROW's experienced management, robust pipeline, and expanding marke...

Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 11, 2025 Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 11, 2025

Harrow's recent debt refinancing, Melt Pharmaceuticals acquisition plans, and updated peak sales estimates reinforce the bullish thesis. Base case DCF modeling projects significant revenue growth through 2034, with relatively conservative assumptions on margins and product adoption. I reiterate a "Buy" rating for HROW stock, with ~88% upside to a $72.7 base case fair value, including some risk ...

Frank Mullery Appointed Chief Executive Officer of ImprimisRx Bridseida Cruz Appointed Head of Quality of ImprimisRx NASHVILLE, Tenn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced leadership changes at its wholly-owned subsidiary, ImprimisRx.

Harrow, Inc. (NASDAQ:HROW ) Analyst/Investor Day September 26, 2025 11:30 AM EDT Company Participants Michael Biega - Vice President of Investor Relations & Communications Mark Baum - CEO & Chairman of the Board Andrew Boll - President, CFO & Corporate Secretary Conference Call Participants Mayank Mamtani - B. Riley Securities, Inc., Research Division Steven Seedhouse - Cantor Fitzgerald & Co.,...